Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.

Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI.

J Clin Oncol. 2010 Mar 20;28(9):1496-501. doi: 10.1200/JCO.2009.25.9259. Epub 2010 Feb 16.

2.

[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].

Boissier E, Loriot Y, Vignot S, Massard C.

Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Review. French.

PMID:
24793632
3.

Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.

Zhou ZR, Liu SX, Zhang TS, Xia J, Li B.

Asian Pac J Cancer Prev. 2014;15(3):1313-20. Review.

4.

EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.

Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N; European Association of Urology..

Eur Urol. 2014 Feb;65(2):467-79. doi: 10.1016/j.eururo.2013.11.002. Epub 2013 Nov 12. Review.

PMID:
24321502
5.

Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.

Perletti G, Monti E, Marras E, Cleves A, Magri V, Trinchieri A, Rennie PS.

Arch Ital Urol Androl. 2015 Jul 7;87(2):121-9. doi: 10.4081/aiua.2015.2.121. Review.

6.

Novel therapeutic strategies for metastatic prostate cancer in the post-docetaxel setting.

Sartor O, Michels RM, Massard C, de Bono JS.

Oncologist. 2011;16(11):1487-97. doi: 10.1634/theoncologist.2010-0412. Epub 2011 Nov 2. Review.

7.

Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.

Hoy SM.

Drugs. 2013 Dec;73(18):2077-91. doi: 10.1007/s40265-013-0150-z. Review.

PMID:
24271422
8.
9.

Abiraterone acetate and prednisone in chemotherapy-naïve prostate cancer patients: rationale, evidence and clinical utility.

Crawford ED, Shore ND, Petrylak DP, Higano CS, Ryan CJ.

Ther Adv Med Oncol. 2017 May;9(5):319-333. doi: 10.1177/1758834017698644. Epub 2017 Mar 22. Review.

10.

Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer.

Auchus RJ, Yu MK, Nguyen S, Mundle SD.

Oncologist. 2014 Dec;19(12):1231-40. doi: 10.1634/theoncologist.2014-0167. Epub 2014 Oct 31. Review.

11.

Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer.

Antonarakis ES, Armstrong AJ.

Prostate Cancer Prostatic Dis. 2011 Sep;14(3):192-205. doi: 10.1038/pcan.2011.23. Epub 2011 May 17. Review.

12.

CYP17 blockade by abiraterone: further evidence for frequent continued hormone-dependence in castration-resistant prostate cancer.

Ang JE, Olmos D, de Bono JS.

Br J Cancer. 2009 Mar 10;100(5):671-5. doi: 10.1038/sj.bjc.6604904. Epub 2009 Feb 17. Review.

13.

The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.

Bird IM, Abbott DH.

J Steroid Biochem Mol Biol. 2016 Oct;163:136-46. doi: 10.1016/j.jsbmb.2016.04.021. Epub 2016 May 3. Review.

PMID:
27154414

Supplemental Content

Support Center